Monthly Archives: October 2013

UK Bioscience Forum: Confronting Common Challenges

Jim_London115x76

This week, BIO’s President and CEO Jim Greenwood delivered a plenary address to attendees at the UK Bioscience Forum in London, England. Below are excerpts from his speech: We can work together to build the right framework to support innovation. From the way we fund research, to how we protect innovations, to how we attract investment and streamline regulatory approval. The UK has the right innovation ecosystem in place to grow as a global biotech Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

Crowdfunding in Health Care and Biotechnology

JobsAct_photo_115x76

Smaller private companies are constantly in search of capital, but many find it difficult to navigate the step between a “friends and family” round or one with angels and an initial venture round. Crowdfunding has been used in a limited number of examples for life sciences companies, but where is this pathway heading? How should a company look at opportunities for crowdfunding? During the 12th annual BIO Investor Forum, a CEO moderator, Nicholas Franano of Novita Read More >

Business and Investments  |  1 Comment  |  Email This Post
Tags: , , , , , ,

Confused Consumers are a Desirable Bonus of I-522

No-on-522-2 copy

With less than a month out, Washington State Initiative 522 continues to garner more and more attention of state voters. If enacted, the law would require labeling of genetically engineered foods on the packaging of raw agricultural commodities, processed foods, and seed and seed stock, or on retail shelf signage for unpackaged products. Exemptions to these regulations would be provided under the measure.  If found in violation of not meeting the labeling requirements, offenders could Read More >

Food And Agriculture  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The New Road to IPO in the Age of the JOBS Act

President Obama

Not surprisingly, sessions discussing the topic of IPOs at this year’s BIO Investor Forum, tend to fill the room. Furthermore, it should surprise no one that this year’s IPO discussions were upbeat. That is mostly attributable to the dramatically higher number of IPOs that have already occurred this year. Furthermore, according to Jeff Baumel, moderator of a panel covering this very topic, deals are closing faster this year – with a median time of just Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO Patient and Health Advocacy Summit: Patient-Focused Drug Development

95468934

Panelists in this morning’s opening session outlined strategies for the FDA to better engage the patient community to guide the drug development process. “Patients should be providing input and guidance throughout the entire drug review process,” said Marc Boutin, Executive VP and COO of the National Health Council. Boutin highlighted the improvements made through PDUFA V to open up and enhance the Agency’s interaction and engagement with patients. “Integrating our perspective into how drugs are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,